Antoon J M van Oosterhout
Overview
Explore the profile of Antoon J M van Oosterhout including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hesse L, Oude Elberink J, van Oosterhout A, Nawijn M
Pharmacol Ther
. 2022 Jan;
237:108115.
PMID: 35063570
Allergic respiratory diseases, such as allergic dermatitis, food allergy, allergic rhino conjunctivitis and allergic asthma, are chronic inflammatory diseases with increasing prevalence. Symptoms include such as watery or itchy itching...
2.
Wellaway C, Baldwin I, Bamborough P, Barker D, Bartholomew M, Chung C, et al.
J Med Chem
. 2021 Dec;
65(1):633-664.
PMID: 34928601
The Janus family of tyrosine kinases (JAK1, JAK2, JAK3, and TYK2) play an essential role in the receptor signaling of cytokines that have been implicated in the pathogenesis of severe...
3.
Hesse L, van Ieperen N, Petersen A, Oude Elberink J, van Oosterhout A, Nawijn M
Sci Rep
. 2020 Dec;
10(1):20876.
PMID: 33257771
Allergen-specific immunotherapy (AIT) has the potential to provide long-term protection against allergic diseases. However, efficacy of AIT is suboptimal, while application of high doses allergen has safety concerns. The use...
4.
Hesse L, Petersen A, Oude Elberink J, van Oosterhout A, Nawijn M
Sci Rep
. 2020 Jun;
10(1):8960.
PMID: 32488022
Allergen specific immunotherapy (AIT) can provide long-term alleviation of symptoms for allergic disease but is hampered by suboptimal efficiency. We and others have previously shown that 1,25(OH)2-VitaminD3 (VitD3) can improve...
5.
Kerscher B, Barlow J, Rana B, Jolin H, Gogoi M, Bartholomew M, et al.
Front Immunol
. 2019 Apr;
10:678.
PMID: 31024538
Group 2 innate lymphoid cells (ILC2) increase in frequency in eczema and allergic asthma patients, and thus represent a new therapeutic target cell for type-2 immune-mediated disease. The bromodomain and...
6.
Pouwels S, Faiz A, den Boef L, Gras R, van den Berge M, Boezen H, et al.
Am J Physiol Lung Cell Mol Physiol
. 2017 Jun;
313(3):L559-L580.
PMID: 28596295
Chronic obstructive pulmonary disease (COPD) is characterized by unresolved neutrophilic airway inflammation and is caused by chronic exposure to toxic gases, such as cigarette smoke (CS), in genetically susceptible individuals....
7.
Schwarze J, Fitch P, Heimweg J, Errington C, Matsuda R, de Bruin H, et al.
Eur Respir J
. 2016 Nov;
48(6):1785-1788.
PMID: 27824598
No abstract available.
8.
Pouwels S, Hesse L, Faiz A, Lubbers J, Bodha P, Ten Hacken N, et al.
Am J Physiol Lung Cell Mol Physiol
. 2016 Sep;
311(5):L881-L892.
PMID: 27612964
Cigarette smoke (CS) exposure is a major risk factor for chronic obstructive pulmonary disease (COPD). We investigated whether CS-induced damage-associated molecular pattern (DAMP) release or DAMP-mediated inflammation contributes to susceptibility...
9.
Hoonhorst S, Lo Tam Loi A, Pouwels S, Faiz A, Telenga E, van den Berge M, et al.
Respir Res
. 2016 Apr;
17:46.
PMID: 27117828
Background: Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by chronic airway inflammation and emphysema, and is caused by exposure to noxious particles or gases, e.g. cigarette...
10.
Pouwels S, Zijlstra G, van der Toorn M, Hesse L, Gras R, Ten Hacken N, et al.
Am J Physiol Lung Cell Mol Physiol
. 2016 Jan;
310(4):L377-86.
PMID: 26719146
Recent data indicate a role for airway epithelial necroptosis, a regulated form of necrosis, and the associated release of damage-associated molecular patterns (DAMPs) in the development of chronic obstructive pulmonary...